NNP
IONS icon

Nachman Norwood & Parrott’s Ionis Pharmaceuticals IONS Stock Holding History

Nachman Norwood & Parrott’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-549
Closed -$26K – 631
2020
Q3 		$26K Buy
+549
New +$30.5K ﹤0.01% 570

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Nachman Norwood & Parrott's IONS Position: Q4 2020 in Review

Nachman Norwood & Parrott sold out of Ionis Pharmaceuticals (IONS) in Q4 2020, closing a stake of 549 shares — an estimated $26K sold.

Nachman Norwood & Parrott first reported a position in IONS in Q3 2020 and held it in 1 quarter. The position peaked at $26K in Q3 2020. 382 funds tracked by Wall St. Rank hold IONS as of Q4 2020.

  • Nachman Norwood & Parrott reported no remaining Ionis Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Nachman Norwood & Parrott sold 549 Ionis Pharmaceuticals shares in Q4 2020, an estimated $26K.
  • Nachman Norwood & Parrott first reported a position in Ionis Pharmaceuticals in Q3 2020 and held it in 1 quarter.
  • Nachman Norwood & Parrott's Ionis Pharmaceuticals position peaked at $26K in Q3 2020.
  • 382 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2020.

Based on Nachman Norwood & Parrott's 13F filing for Q4 2020, filed 19 Jan 2021.